Last reviewed · How we verify
NCT05397613
STAIR for Trauma and Emotion Dysregulation
NA trial testing STAIR in Posttraumatic Stress Disorder in 30 participants. Status unknown.
15 June 2025
Quick facts
| Lead sponsor | Stanford University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 15 June 2022 |
| Primary completion | 15 June 2025 |
| Estimated completion | 15 June 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- STAIR
Conditions studied
- Posttraumatic Stress Disorder — all drugs for Posttraumatic Stress Disorder →
- Borderline Personality Disorder — all drugs for Borderline Personality Disorder →
- Emotion Regulation — all drugs for Emotion Regulation →
Sponsor
Stanford University
Who can join
18 and older, any sex, with Posttraumatic Stress Disorder or Borderline Personality Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will examine the impact of Skills Training in Affective and Interpersonal Regulation (STAIR) group, using self-report measures, on Posttraumatic Stress Disorder (PTSD), emotional dysregulation, borderline personality disorder symptoms, global psychopathology, and access to quality mental health care. Aims include assessing the feasibility of STAIR, reducing patients' trauma and emotion dysregulation symptoms, examining whether STAIR may be used as an alternative to DBT for patients on the DBT, and improving patient satisfaction and clinic efficiency
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05397613
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Posttraumatic Stress Disorder
Currently open trials in the same condition.
- NCT04529031 — Biomolecular Characteristics of Reminder-Focused Positive-Psychiatry · NA · recruiting
- NCT06219408 — CIH Stepped Care for Co-occurring Chronic Pain and PTSD · NA · recruiting
- NCT07176273 — Adaptive Decision-making And Personalized Treatment for PTSD (ADAPT-PTSD) · NA · recruiting
- NCT07105345 — Exploring Efficacy of Multi-Mode Cognitive Processing Therapy (CPT) for PTSD · NA · recruiting
- NCT06608277 — Ketamine, SGB and Combination Treatment for TBI · Phase 2 · recruiting
Other Stanford University trials
Trials by the same sponsor.
- NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
- NCT04225949 — Patients Understanding of PROM Graphs · NA · withdrawn
- NCT06273098 — School-Based Bladder Health Intervention · NA · withdrawn
- NCT04652635 — Management of Nailbed Injuries · NA · withdrawn
- NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain · NA · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05397613 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Stanford University
- Last refreshed: 31 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05397613.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing